Lodovico Balducci

Dr. Lodovico Balducci


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Surgical Oncology
Verified
Journal Article
Closed access
LBLodovico Balducci
Lodovico Balducci
GCGiuseppe Colloca
Giuseppe Colloca
MCMatteo Cesari
Matteo Cesari
GGGiovanni Gambassi
Giovanni Gambassi

1 July 2014 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
MPMihaela A. Popa
Mihaela A. Popa
KWKristie J. Wallace
Kristie J. Wallace
Antonella BrunelloAntonella Brunello
Antonella Brunello
MEMartine Extermann
Martine Extermann
LBLodovico Balducci
Lodovico Balducci

1 October 2013 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
LBLodovico Balducci
Lodovico Balducci
DGD. Goetz-Parten
D. Goetz-Parten
MSM. A. Steinman
M. A. Steinman
Aging is associated with polymorbidity and polypharmacy. In the absence of a consensual definition, polypharmacy has been defined according to the number of drugs that an individual takes or to the presence of the risk of at least one severe drug interaction. In older cancer patients, polypharmacy is at least as common as it is in individuals of the same age without cancer. The management of cancer itself may result in the addition of more medications to counteract the adverse effects of antineoplastic treatment. Polypharmacy may be necessary to control the multiple health conditions of the older person, but it may represent a risk factor for more complications from antineoplastic therapy, and it may affect the outcome of cancer treatment. Polypharmacy is also associated with increased cost. The criteria proposed for the management of polypharmacy include the assessment that all medical conditions are properly treated, the avoidance of drug interactions, and of drugs that may compromise the outcome of antineoplastic treatment and the choice of drugs with the lowest risk of complications in older individuals.

1 January 2019 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
LBLodovico Balducci
Lodovico Balducci

1 April 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
LBLodovico Balducci
Lodovico Balducci
A good death and a death with dignity may be achieved when death is congruent with the personal values of the patient. It behooves the practitioner to recognize these values and to cater to them. This paper describes effective communication with the dying person, and the partnership of treatment team, patient and family in face of the patient death. To identify and define the patient wishes it is necessary to learn how to interpret the patient's non verbal as often patients are unable to formulate the questions they wish to ask concerning their passing. These difficulties stem from several cultural factors including concern about disturbing the practitioner. It is the treatment team's responsibility to facilitate this discussion. A good death is achieved when symptoms are controlled and when patients and family recognize death as a unique living experience to be treasured as any other living experience. A death with dignity brings healing, that is always possible even when cure is out of reach. Patient's and practitioner's values may be at odd in face of controversial issues including euthanasia, assisted suicide and terminal sedation. Though he/she should not be compelled to execute these requests, the practitioner should be able to entertain an open discussion with the patient concerning these issues. Open communication and reflective listening even in presence of disagreements are the venue of healing. The study of death and dying requires novel approaches including personal narrative and qualitative research to complement traditional research instrument, such as questionnaire that cannot embrace the whole human dimension.

1 July 2014 in Cancer Control
Verified
Journal Article
Open access
LBLodovico Balducci
Lodovico Balducci
Data relating to cancer treatment in the older patient population are limited because older individuals have been under-represented in clinical trials. The goal of this review was to establish which factors hinder the participation of older individuals to clinical trials and to examine possible solutions. The literature relating to cancer treatment in the older patient population was reviewed. The benefit of systemic cancer treatment may decrease with age, and risks may be increased due to reduced life expectancy and reduced tolerance of stress in the older population. Therefore, a multipronged approach is recommended for clinical studies in these patients, including phase 2 studies limited to persons 70 years of age and older, stratification by life expectancy and predicted treatment tolerance in phase 3 studies, and registration studies to establish predictive variables for treatment-related toxicity in older individuals. A combination of prospective and registration studies may supply adequate information to study cancer treatments in the older patient population.